Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Jinhyun | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Park, Silvia | - |
dc.contributor.author | Yoo, Kwai Han | - |
dc.contributor.author | Ki, Chang-Seok | - |
dc.contributor.author | Ko, Younghyeh | - |
dc.contributor.author | Kim, Won Seog | - |
dc.date.available | 2020-02-27T09:42:38Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2018-08 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3494 | - |
dc.description.abstract | Circulating Epstein-Barr virus (EBV)-DNA has been established as a useful parameter for diagnosis and predicting prognosis in patients with extranodal natural killer T cell lymphoma (ENKTL); however, the role of monitoring of circulating EBV-DNA after complete remission (CR) is not well established. From January 2008 to August 2016, 328 ENKTL patents were enrolled in 2 lymphoma cohorts. Of 171 patients achieved a CR, 81 had available monitoring data for circulating EBV-DNA with negative post-treatment EBV-DNA. Measurement of circulating EBV-DNA was performed from unfractionated whole blood and calculated according to WHO international standards. Median duration of follow-up was 40.4 months. In 31 of the 81 patients (38.8%), circulating EBV-DNA was detected at least once during follow-up, and 16 of these patients (51.6%) experienced relapse. In contrast, only 7 out of 50 (14.0%) patients with consistently undetectable circulating EBV-DNA experienced relapse (p < 0.001). In multivariate analysis, positive conversion of circulating EBV-DNA was the only independent prognostic factor for occurrence of relapse (HR = 6.552, p < 0.001), progression-free survival (HR = 4.549, p = 0.01), and overall survival (HR = 8.726, p < 0.001). Patients with a higher level of circulating EBV-DNA than 3310 IU/mL (3.52 log(10) IU/mL) showed a strong tendency to relapse (73.3 vs. 31.3%, p = 0.019). In conclusion, positive conversion of circulating EBV-DNA was a valuable indicator of relapse and inferior survival, especially if the level was higher than 3310 IU/mL in ENKTL patients had achieved CR. Close follow-up is necessary for patients developed detectable circulating EBV-DNA after remission. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.subject | POLYMERASE-CHAIN-REACTION | - |
dc.subject | BLOOD MONONUCLEAR-CELLS | - |
dc.subject | EBV-DNA | - |
dc.subject | PERIPHERAL-BLOOD | - |
dc.subject | WHOLE-BLOOD | - |
dc.subject | NASAL TYPE | - |
dc.subject | LYMPHOPROLIFERATIVE DISEASE | - |
dc.subject | RETROSPECTIVE ANALYSIS | - |
dc.subject | VIRAL LOAD | - |
dc.subject | PLASMA | - |
dc.title | Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000436235400013 | - |
dc.identifier.doi | 10.1007/s00277-018-3313-x | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.97, no.8, pp.1427 - 1436 | - |
dc.identifier.scopusid | 2-s2.0-85045073189 | - |
dc.citation.endPage | 1436 | - |
dc.citation.startPage | 1427 | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 97 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Yoo, Kwai Han | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | NK/Tcell lymphoma | - |
dc.subject.keywordAuthor | EBV | - |
dc.subject.keywordAuthor | PCR | - |
dc.subject.keywordAuthor | Biomarker | - |
dc.subject.keywordAuthor | Relapse | - |
dc.subject.keywordPlus | POLYMERASE-CHAIN-REACTION | - |
dc.subject.keywordPlus | BLOOD MONONUCLEAR-CELLS | - |
dc.subject.keywordPlus | EBV-DNA | - |
dc.subject.keywordPlus | PERIPHERAL-BLOOD | - |
dc.subject.keywordPlus | WHOLE-BLOOD | - |
dc.subject.keywordPlus | NASAL TYPE | - |
dc.subject.keywordPlus | LYMPHOPROLIFERATIVE DISEASE | - |
dc.subject.keywordPlus | RETROSPECTIVE ANALYSIS | - |
dc.subject.keywordPlus | VIRAL LOAD | - |
dc.subject.keywordPlus | PLASMA | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.